Nasal congestion decreases quality of life to a great extent. You can’t breathe normally, experience headaches caused by the lack of oxygen, and cannot feel the taste of food. Nasal drops and sprays are number one treatment in this case but are they absolutely safe? Unfortunately, the majority of non-homeopathy remedies cause side effects. Find out how to diminish those and finally to start breathing […]
Most of the world regards the notion “generic” as something of poor quality, bland or compromised but to the pharmaceutical industry, generic is akin to a virtual panacea. Today, generic drug manufacturing is a high-volume business capturing the global pharmaceutical market and adequately competing with branded medications. The generic drug production calls for excellent manufacturing and scientific skills, full-featured research and development, and superior regulatory […]
It is well established that taking antidepressants is fraught with such serious side effects as erectile dysfunction (ED), decrease in sexual desire and anorgasmia in men. This article is dedicated to concomitant use of antidepressive drug Zoloft (sertraline) and Viagra (sildenafil), when depression therapy is required to continue and erectile function should be restored. Zoloft and Viagra: a popular therapy tandem Let us first understand […]
Iselin NJ, August 8, 2011 – Pharmos Corporation (OTC-PINK: PARS.PK) today reported financial results for the second quarter and six-month period ended June 30, 2011. These results are included in the Company’s Quarterly Report on Form 10-Q which has been filed with the SEC. Second Quarter Ended June 30, 2011 The Company recorded a net loss of $0.5 million, or $0.01 per share, for the second […]
Iselin NJ, April 28, 2011 – Pharmos Corporation (OTCBB: PARS.PK) ISELIN, N.J., April 28, 2011 /PRNewswire/ — Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the first quarter ended March 31, 2011. The Company recorded a net loss of $0.6 million, or $0.01 per share, for the first quarter 2011 compared to a net loss of $0.5 million, or $0.01 per share, in the […]
Iselin NJ, February 17, 2011 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2010. These results are included in the Company’s Yearly Report on Form 10-K which has been filed with the SEC. Fourth Quarter Ended December 31, 2010 The Company recorded a net loss of $152,000, or $0.00 per share, for the fourth quarter […]
Iselin NJ, October 27, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the third quarter and nine-month period ended September 30, 2010. These results are included in the Company’s Quarterly Report on Form 10-Q which has been filed with the SEC. During the quarter the Company kept expenses to a minimum level while pursuing potential partners for Dextofisopam, its drug for irritable bowel […]
Iselin NJ, August 4, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the second quarter and six-month period ended June 30, 2010. These results are included in the Company’s Quarterly Report on Form 10-Q which has been filed with the SEC. During the quarter the Company kept expenses to a minimum level while pursuing potential partners for Dextofisopam, its drug for irritable bowel […]
Iselin NJ, May 12, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the first quarter ended March 31, 2010. The Company recorded a net loss of $0.5 million, or $0.01 per share, for the first quarter 2010 compared to a net loss of $3.7 million, or $0.14 per share, in the first quarter 2009. Research & development expenses decreased by $1,891,425 or 94% […]
Iselin NJ, February 22, 2010 – Pharmos Corporation (OTCBB: PARS.PK) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2009. Fourth Quarter Ended December 31, 2009 Pharmos has no revenues at this time. The fourth quarter net income is partly due to a renegotiated milestone requirement that is not expected to be met and the resulting reversal of a previously recorded […]